title: Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal.
authors.affiliation: a Department of Pharmacy , Radboud University Medical Center , Nijmegen , The Netherlands.
authors.forename: Floor J E
authors.initials: FJE
authors.lastname: Lubberman
authors.affiliation: a Department of Pharmacy , Radboud University Medical Center , Nijmegen , The Netherlands.
authors.forename: Nielka P
authors.initials: NP
authors.lastname: van Erp
authors.affiliation: a Department of Pharmacy , Radboud University Medical Center , Nijmegen , The Netherlands.
authors.forename: Rob
authors.initials: R
authors.lastname: Ter Heine
authors.affiliation: b Department of Medical Oncology , Radboud University Medical Center , Nijmegen , The Netherlands.
authors.forename: Carla M L
authors.initials: CML
authors.lastname: van Herpen
mesh_terms: D000077784:Axitinib / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D000069547:Cobicistat / Q000008:administration & dosage*; D065692:Cytochrome P-450 CYP3A Inhibitors / Q000008:administration & dosage*; D004357:Drug Synergism; D017809:Fatal Outcome; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods; D057285:Precision Medicine / Q000379:methods*
chemical_list: D065692:Cytochrome P-450 CYP3A Inhibitors; D000077784:Axitinib; D000069547:Cobicistat